IRIS
GIULIANO, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.787
EU - Europa 1.116
AS - Asia 557
AF - Africa 41
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.502
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.762
IT - Italia 714
SG - Singapore 293
CN - Cina 178
NL - Olanda 122
DE - Germania 64
IE - Irlanda 56
FI - Finlandia 43
CI - Costa d'Avorio 41
VN - Vietnam 36
IN - India 27
FR - Francia 24
SE - Svezia 24
CA - Canada 22
GB - Regno Unito 19
UA - Ucraina 12
BE - Belgio 5
ES - Italia 5
PK - Pakistan 5
CZ - Repubblica Ceca 4
HK - Hong Kong 4
JP - Giappone 4
PL - Polonia 4
AL - Albania 3
BZ - Belize 3
DK - Danimarca 3
MY - Malesia 3
RS - Serbia 3
BG - Bulgaria 2
IR - Iran 2
IS - Islanda 2
MK - Macedonia 2
PH - Filippine 2
RU - Federazione Russa 2
AM - Armenia 1
EU - Europa 1
GR - Grecia 1
HU - Ungheria 1
IL - Israele 1
MC - Monaco 1
TW - Taiwan 1
Totale 3.502
Salva come PNG Salva come JPEG
Città #
Chandler 426
Singapore 241
Napoli 127
Amsterdam 121
Naples 116
Millbury 113
Ashburn 103
Beijing 64
Princeton 55
Des Moines 52
Santa Clara 48
Nanjing 41
Wilmington 37
Dong Ket 36
Lawrence 34
Pune 25
Boston 23
Rome 20
Milan 18
Ottawa 18
Jacksonville 17
Casoria 13
Formia 13
Pomigliano d'Arco 13
Dearborn 11
Nanchang 11
Seattle 11
Shenyang 9
Villaricca 9
Woodbridge 9
Boardman 8
Caserta 8
Hebei 8
Jiaxing 8
Redwood City 8
Tianjin 8
Bologna 7
Fairfield 7
Kronberg 7
Salerno 7
Sant'Agnello 7
Changsha 6
Massa di Somma 6
Somma Vesuviana 6
Genoa 5
Washington 5
Angri 4
Battipaglia 4
Brescia 4
Dallas 4
Dublin 4
Falls Church 4
Kortrijk 4
Lappeenranta 4
Los Angeles 4
Marano di Napoli 4
New York 4
Norwalk 4
Sciacca 4
Seregno 4
Veroli 4
Ancona 3
Augusta 3
Belize City 3
Brno 3
Chiaravalle Centrale 3
Granada 3
Hong Kong 3
Indiana 3
Kuala Lumpur 3
Lahore 3
Luco dei Marsi 3
Menlo Park 3
Pellezzano 3
San Jose 3
Shanghai 3
Siena 3
Springfield 3
Tirana 3
Bacoli 2
Castelnuovo del Garda 2
Changchun 2
Chengdu 2
Duncan 2
Formello 2
Fort Worth 2
General Mariano Alvarez 2
Kagoya 2
Krefeld 2
Leawood 2
Lomazzo 2
Montalbano Jonico 2
Novi Sad 2
Orange 2
Palermo 2
Palma Campania 2
Pavullo Nel Frignano 2
Ravenna 2
Reykjavik 2
Richmond 2
Totale 2.101
Salva come PNG Salva come JPEG
Nome #
Epigenetic silencing of THY1 tracks the acquisition of the Notch1-EGFR signaling in a xenograft model of CD44+/CD24low/CD90+ myoepithelial cells 92
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy 89
Bowel obstruction and peritoneal carcinomatosis in the elderly. A systematic review 87
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. 79
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 65
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 63
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 60
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results 51
The Impact of Translational Research in Breast Cancer Care: Can We Improve the Therapeutic Scenario? 50
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer 49
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 49
A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA 49
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis 47
The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment 46
Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications 46
Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study 45
Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues 45
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 45
Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study 44
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: An open-label, 2 × 2 factorial, randomised phase 3 trial 44
R0 surgical resection of giant dedifferentiated retroperitoneal liposarcomas in the COVID era with and without nephrectomy: A case report 43
Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with Anti-HER2 therapy 43
Tumori maligni del colon 43
Systemic treatment of malignant gastrointestinal neuroectodermal tumour after childhood neuroblastoma: chemotherapy in malignant gastrointestinal neuroectodermal tumour 43
It is no longer the time to disregard thyroid metastases from breast cancer: A case report and review of the literature 42
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 42
Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. 40
Mechanisms of lapatinib resistance in HER2-driven breast cancer 40
Long-term survival and BRCA status in male breast cancer: A retrospective single-center analysis 40
Blockade of AP-1 potentiates endocrine therapy and overcomes resistance 40
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. 39
Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women 39
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis 39
Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis 38
Circulating tumor cells in newly diagnosed inflammatory breast cancer 38
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 38
Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination 37
Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives 37
Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity? 36
Tumor characteristics and prognosis in familial breast cancer 36
Combined effect of obesity and diabetes on early breast cancer outcome: A prospective observational study 36
A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer 36
Assessment of Total, PTEN–, and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide 36
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 36
Heterogeneity of SSTR2 expression assessed by 68Ga-DOTATOC PET/CT using coefficient of variation in patients with neuroendocrine tumors 36
A djuvant treatment in patients at high risk of recurrence of thymoma: Efficacy and safety of a three-dimensional conformal radiation therapy regimen 35
Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction 35
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. 33
Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer. 33
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis 33
Biological mechanisms and clinical implications of endocrine resistance in breast cancer. 33
Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study 33
The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug? 32
Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype 32
FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. 32
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase 32
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series 32
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 32
Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. 30
PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom? 30
Boosting the immune response with the combination of electrochemotherapy and immunotherapy: A new weapon for squamous cell carcinoma of the head and neck? 30
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 29
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials 29
Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy 29
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications. 28
Circulating tumor cells (CTC) are associated with defects in adaptive immunity in patients with inflammatory breast cancer 28
Prevalence of Sarcopenia in Women with Breast Cancer 27
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer 26
Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer. 26
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. 26
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. 26
Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer 26
Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer 26
Fine-Needle Aspiration Is Suitable for Breast Cancer BRCA Molecular Assessment: A Case Report 26
Mammary Adipose Tissue Control of Breast Cancer Progression: Impact of Obesity and Diabetes 25
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 25
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays? 24
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis 24
Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis 24
Optimal multidisciplinary treatment of oral cavity mucosal melanoma: Outcome analysis in a case series 23
Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. 22
Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications. 22
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study 21
Extraskeletal Ewing's sarcoma of the mediastinum: Case report 21
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. 21
Epigenetic control of gene expression: Potential implications for cancer treatment 21
Endocrine‐based treatments in clinically‐relevant subgroups of hormone receptor‐positive/her2‐negative metastatic breast cancer: Systematic review and meta‐analysis 21
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials 20
Die and let live: harnessing BikDD to combat breast cancer stem cells. 19
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. 19
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: exploratory analysis of the GIM2 trial 19
Therapeutic potential of the dual EGFR/HER2?inhibitor AZD8931 in circumventing endocrine resistance. 18
Metastasis dormancy in estrogen receptor-positive breast cancer. 18
Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do? 18
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer 17
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054] 17
Genetics and management of locally advanced carcinomas of the head and neck: Role of altered fractionation radiotherapy 17
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 16
Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests 16
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation 15
Totale 3.510
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.042
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.042
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020230 0 0 21 16 26 23 11 18 15 31 54 15
2020/2021276 7 1 26 24 28 18 28 13 49 17 20 45
2021/2022600 9 4 17 9 6 24 14 23 69 60 154 211
2022/20231.005 97 89 37 64 128 104 18 95 146 150 53 24
2023/2024787 33 120 96 51 42 102 11 75 23 24 130 80
2024/2025356 168 176 12 0 0 0 0 0 0 0 0 0
Totale 3.736